{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:14:24Z","timestamp":1793744064988,"version":"4.6.1"},"reference-count":145,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013365","name":"Sichuan University West China Hospital","doi-asserted-by":"publisher","award":["ZYJC21020"],"award-info":[{"award-number":["ZYJC21020"]}],"id":[{"id":"10.13039\/501100013365","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005150","name":"Chinese Academy of Medical Sciences","doi-asserted-by":"publisher","award":["T-B-098"],"award-info":[{"award-number":["T-B-098"]}],"id":[{"id":"10.13039\/501100005150","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005150","name":"Chinese Academy of Medical Sciences","doi-asserted-by":"publisher","award":["2022\\u201312M-C"],"award-info":[{"award-number":["2022\\u201312M-C"]}],"id":[{"id":"10.13039\/501100005150","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81974398"],"award-info":[{"award-number":["81974398"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82203110"],"award-info":[{"award-number":["82203110"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172785"],"award-info":[{"award-number":["82172785"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004912","name":"Sichuan University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004912","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012542","name":"Sichuan Province Science and Technology Support Program","doi-asserted-by":"publisher","award":["2021YFS0119"],"award-info":[{"award-number":["2021YFS0119"]}],"id":[{"id":"10.13039\/100012542","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.critrevonc.2025.104698","type":"journal-article","created":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T21:08:21Z","timestamp":1741900101000},"page":"104698","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Empowering PARP inhibition through rational combination: Mechanisms of PARP inhibitors and combinations with a focus on the treatment of metastatic castration-resistant prostate cancer"],"prefix":"10.1016","volume":"210","author":[{"given":"Jinge","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengfei","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.critrevonc.2025.104698_bib1","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.molcel.2015.01.034","article-title":"Biology of poly(ADP-ribose) polymerases: the factotums of cell maintenance","volume":"58","author":"Bai","year":"2015","journal-title":"Mol. Cell"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104698_bib2","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.hoc.2012.02.012","article-title":"Poly(adenosine diphosphate-ribose) polymerase inhibitors in cancer treatment","volume":"26","author":"Park","year":"2012","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"10.1016\/j.critrevonc.2025.104698_bib3","unstructured":"US Food and Drug Administration. LYNPARZA\u00ae (olaparib) tablets, for oral use. AstraZeneca. \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/208558s014lbl.pdf\u3009."},{"key":"10.1016\/j.critrevonc.2025.104698_bib4","unstructured":"US Food and Drug Administration. RUBRACA\u00ae (rucaparib) tablets, for oral use. Clovis Oncology, Inc. \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/209115s011lbl.pdf\u3009."},{"key":"10.1016\/j.critrevonc.2025.104698_bib5","unstructured":"FDA approves niraparib and abiraterone acetate plus prednisone for BRCA-mutated metastatic castration-resistant prostate cancer. Released on August 11, 2023. \u3008https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-niraparib-and-abiraterone-acetate-plus-prednisone-brca-mutated-metastatic-castration\u3009."},{"key":"10.1016\/j.critrevonc.2025.104698_bib6","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/4986365","article-title":"BRCA mutations in prostate cancer: Prognostic and predictive implications","author":"Messina","year":"2020","journal-title":"J. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104698_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12020394","article-title":"PARP inhibitors as therapeutics: beyond modulation of PARylation","volume":"12","author":"Min","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"25","key":"10.1016\/j.critrevonc.2025.104698_bib8","doi-asserted-by":"crossref","first-page":"23028","DOI":"10.1074\/jbc.M202390200","article-title":"Poly(ADP-ribose) polymerase-2 (PARP-2) is required for efficient base excision DNA repair in association with PARP-1 and XRCC1","volume":"277","author":"Schreiber","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"25","key":"10.1016\/j.critrevonc.2025.104698_bib9","doi-asserted-by":"crossref","first-page":"17860","DOI":"10.1074\/jbc.274.25.17860","article-title":"PARP-2, A novel mammalian DNA damage-dependent poly(ADP-ribose) polymerase","volume":"274","author":"Ame","year":"1999","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104698_bib10","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/nrc2812","article-title":"PARP inhibition: PARP1 and beyond","volume":"10","author":"Rouleau","year":"2010","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104698_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12010183","article-title":"PARylation during transcription: insights into the fine-tuning mechanism and regulation","volume":"12","author":"Pahi","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104698_bib12","first-page":"1842","article-title":"Understanding specific functions of PARP-2: new lessons for cancer therapy","volume":"6","author":"Ali","year":"2016","journal-title":"Am. J. Cancer Res"},{"issue":"18","key":"10.1016\/j.critrevonc.2025.104698_bib13","doi-asserted-by":"crossref","first-page":"4350","DOI":"10.1038\/sj.emboj.7601301","article-title":"PARP-2 deficiency affects the survival of CD4+CD8+\u2009double-positive thymocytes","volume":"25","author":"Yelamos","year":"2006","journal-title":"EMBO J."},{"issue":"52","key":"10.1016\/j.critrevonc.2025.104698_bib14","doi-asserted-by":"crossref","first-page":"37738","DOI":"10.1074\/jbc.M701021200","article-title":"Poly(ADP-ribose) polymerase-2 [corrected] controls adipocyte differentiation and adipose tissue function through the regulation of the activity of the retinoid X receptor\/peroxisome proliferator-activated receptor-gamma [corrected] heterodimer","volume":"282","author":"Bai","year":"2007","journal-title":"J. Biol. Chem."},{"issue":"40","key":"10.1016\/j.critrevonc.2025.104698_bib15","doi-asserted-by":"crossref","first-page":"14854","DOI":"10.1073\/pnas.0604252103","article-title":"Poly(ADP-ribose) polymerase-2 contributes to the fidelity of male meiosis I and spermiogenesis","volume":"103","author":"Dantzer","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"29","key":"10.1016\/j.critrevonc.2025.104698_bib16","doi-asserted-by":"crossref","first-page":"14573","DOI":"10.1073\/pnas.1908547116","article-title":"Selective targeting of PARP-2 inhibits androgen receptor signaling and prostate cancer growth through disruption of FOXA1 function","volume":"116","author":"Gui","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104698_bib17","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1182\/blood-2012-12-472845","article-title":"Parp-2 is required to maintain hematopoiesis following sublethal gamma-irradiation in mice","volume":"122","author":"Farres","year":"2013","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.critrevonc.2025.104698_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241915028","article-title":"The complex network of ADP-ribosylation and DNA repair: emerging insights and implications for cancer therapy","volume":"24","author":"Li","year":"2023","journal-title":"Int J. Mol. Sci."},{"issue":"6486","key":"10.1016\/j.critrevonc.2025.104698_bib19","doi-asserted-by":"crossref","DOI":"10.1126\/science.aax6367","article-title":"Structural basis for allosteric PARP-1 retention on DNA breaks","volume":"368","author":"Zandarashvili","year":"2020","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104698_bib20","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1111\/cas.15477","article-title":"Reconsidering the mechanisms of action of PARP inhibitors based on clinical outcomes","volume":"113","author":"Onji","year":"2022","journal-title":"Cancer Sci."},{"issue":"8007","key":"10.1016\/j.critrevonc.2025.104698_bib21","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41586-024-07217-2","article-title":"Transcription-replication conflicts underlie sensitivity to PARP inhibitors","volume":"628","author":"Petropoulos","year":"2024","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104698_bib22","doi-asserted-by":"crossref","first-page":"4380","DOI":"10.1002\/cam4.5274","article-title":"DNA damage response signaling: A common link between cancer and cardiovascular diseases","volume":"12","author":"Nikfarjam","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.critrevonc.2025.104698_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116288","article-title":"The power and the promise of synthetic lethality for clinical application in cancer treatment","volume":"172","author":"Liu","year":"2024","journal-title":"Biomed. Pharm."},{"issue":"6330","key":"10.1016\/j.critrevonc.2025.104698_bib24","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2025.104698_bib25","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13578-020-00390-7","article-title":"The role of poly(ADP-ribose) polymerase inhibitors in the treatment of cancer and methods to overcome resistance: a review","volume":"10","author":"Patel","year":"2020","journal-title":"Cell Biosci."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104698_bib26","doi-asserted-by":"crossref","DOI":"10.3390\/jpm11121287","article-title":"Race-Specific Genetic Profiles of Homologous Recombination Deficiency in Multiple Cancers","volume":"11","author":"Hsiao","year":"2021","journal-title":"J. Pers. Med"},{"key":"10.1016\/j.critrevonc.2025.104698_bib27","article-title":"Prevalence of homologous recombination-related gene mutations across multiple cancer types","volume":"2018","author":"Heeke","year":"2018","journal-title":"JCO Precis Oncol."},{"issue":"22","key":"10.1016\/j.critrevonc.2025.104698_bib28","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.21037\/atm-21-5449","article-title":"Comprehensive analysis of DNA damage repair deficiency in 10,284 pan-cancer study","volume":"9","author":"Xiao","year":"2021","journal-title":"Ann. Transl. Med"},{"issue":"23","key":"10.1016\/j.critrevonc.2025.104698_bib29","doi-asserted-by":"crossref","first-page":"12628","DOI":"10.3390\/ijms222312628","article-title":"BRCA mutations in prostate cancer: assessment, implications and treatment considerations","volume":"22","author":"Shah","year":"2021","journal-title":"Int J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104698_bib30","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1158\/0008-5472.CAN-19-1840","article-title":"Association of genomic domains in BRCA1 and BRCA2 with prostate cancer risk and aggressiveness","volume":"80","author":"Patel","year":"2020","journal-title":"Cancer Res"},{"issue":"13","key":"10.1016\/j.critrevonc.2025.104698_bib31","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1002\/pros.23204","article-title":"Implications of high rates of metastatic prostate cancer in BRCA2 mutation carriers","volume":"76","author":"Gleicher","year":"2016","journal-title":"Prostate"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104698_bib32","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.molcel.2010.06.017","article-title":"The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets","volume":"39","author":"Krishnakumar","year":"2010","journal-title":"Mol. Cell"},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104698_bib33","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s40265-021-01541-x","article-title":"Fuzuloparib: First Approval","volume":"81","author":"Lee","year":"2021","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104698_bib34","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41392-023-01548-8","article-title":"A new wave of innovations within the DNA damage response","volume":"8","author":"Li","year":"2023","journal-title":"Signal Transduct. Target Ther."},{"issue":"22","key":"10.1016\/j.critrevonc.2025.104698_bib35","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14225559","article-title":"Differences in durability of PARP inhibition by clinically approved PARP inhibitors: implications for combinations and scheduling","volume":"14","author":"Smith","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"36","key":"10.1016\/j.critrevonc.2025.104698_bib36","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abq0414","article-title":"A two-step mechanism governing PARP1-DNA retention by PARP inhibitors","volume":"8","author":"Xue","year":"2022","journal-title":"Sci. Adv."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104698_bib37","article-title":"Multidrug resistance of cancer cells and the vital role of P-glycoprotein","volume":"12","author":"Karthika","year":"2022","journal-title":"Life (Basel)"},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104698_bib38","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.neo.2020.06.009","article-title":"Pamiparib is a potent and selective PARP inhibitor with unique potential for the treatment of brain tumor","volume":"22","author":"Xiong","year":"2020","journal-title":"Neoplasia"},{"issue":"12_ement","key":"10.1016\/j.critrevonc.2025.104698_bib39","article-title":"Abstract 5338: Pamiparib as a non-P-glycoprotein substrate PARP inhibitor can overcome ABCB1-mediated multidrug resistance in ovarian cancer cells","volume":"82","author":"Deng","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.104698_bib40","unstructured":"China National Medical Products Administration. Fluzoparib capsules, for oral use. Jiangsu Hengrui Pharmaceuticals Co., Ltd. \u3008https:\/\/file.wuxuwang.com\/zhuce\/ssypfiles\/a506200167d0708d65375ec7af6c6cc5%E8%AF%B4%E6%98%8E%E4%B9%A6.pdf\u3009."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104698_bib41","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1021\/acsmedchemlett.3c00065","article-title":"Synthesis of veliparib prodrugs and determination of drug-release-dependent PARP-1 inhibition","volume":"14","author":"Borgini","year":"2023","journal-title":"ACS Med Chem. Lett."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104698_bib42","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1158\/1078-0432.CCR-06-3039","article-title":"ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models","volume":"13","author":"Donawho","year":"2007","journal-title":"Clin. Cancer Res"},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104698_bib43","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1124\/dmd.110.037820","article-title":"Disposition and drug-drug interaction potential of veliparib (ABT-888), a novel and potent inhibitor of poly(ADP-ribose) polymerase","volume":"39","author":"Li","year":"2011","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.critrevonc.2025.104698_bib44","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.2147\/OTT.S69935","article-title":"Profile of veliparib and its potential in the treatment of solid tumors","author":"Wagner","year":"2015","journal-title":"Onco Targets Ther. 8"},{"issue":"21","key":"10.1016\/j.critrevonc.2025.104698_bib45","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","article-title":"Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors","volume":"72","author":"Murai","year":"2012","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104698_bib46","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2121979119","article-title":"Inhibitors of PARP: Number crunching and structure gazing","volume":"119","author":"Rudolph","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104698_bib47","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s40487-021-00160-6","article-title":"A narrative review of implementing precision oncology in metastatic castration-resistant prostate cancer in emerging countries","volume":"9","author":"Bazarbashi","year":"2021","journal-title":"Oncol. Ther."},{"key":"10.1016\/j.critrevonc.2025.104698_bib48","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.urolonc.2017.01.020","article-title":"Navigating the evolving therapeutic landscape in advanced prostate cancer","volume":"35S","author":"Crawford","year":"2017","journal-title":"Urol. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104698_bib49","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.annonc.2023.06.009","article-title":"Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial","volume":"34","author":"Chi","year":"2023","journal-title":"Ann. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104698_bib50","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200043","article-title":"Abiraterone and olaparib for metastatic castration-resistant prostate cancer","volume":"1","author":"Clarke","year":"2022","journal-title":"NEJM Evid."},{"key":"10.1016\/j.critrevonc.2025.104698_bib51","unstructured":"US Food and Drug Administration. ZEJULA (niraparib) capsules, for oral use. GlaxoSmithKline. \u3008https:\/\/gskpro.com\/content\/dam\/global\/hcpportal\/en_US\/Prescribing_Information\/Zejula_Capsules\/pdf\/ZEJULA-CAPSULES-PI-PIL.PDF\u3009."},{"key":"10.1016\/j.critrevonc.2025.104698_bib52","unstructured":"US Food and Drug Administration. TALZENNA\u00ae (talazoparib) capsules, for oral use. Pfizer Inc. \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/211651s010lbl.pdf\u3009."},{"issue":"18","key":"10.1016\/j.critrevonc.2025.104698_bib53","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","article-title":"DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer","volume":"373","author":"Mateo","year":"2015","journal-title":"N. Engl. J. Med"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104698_bib54","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1470-2045(19)30684-9","article-title":"Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial","volume":"21","author":"Mateo","year":"2020","journal-title":"Lancet Oncol."},{"issue":"22","key":"10.1016\/j.critrevonc.2025.104698_bib55","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N. Engl. J. Med"},{"issue":"24","key":"10.1016\/j.critrevonc.2025.104698_bib56","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1056\/NEJMoa2022485","article-title":"Survival with olaparib in metastatic castration-resistant prostate cancer","volume":"383","author":"Hussain","year":"2020","journal-title":"N. Engl. J. Med"},{"issue":"32","key":"10.1016\/j.critrevonc.2025.104698_bib57","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1200\/JCO.20.01035","article-title":"Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration","volume":"38","author":"Abida","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104698_bib58","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJMoa2214676","article-title":"T. Investigators, Rucaparib or physician's choice in metastatic prostate cancer","volume":"388","author":"Fizazi","year":"2023","journal-title":"N. Engl. J. Med"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104698_bib59","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S1470-2045(21)00757-9","article-title":"Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial","volume":"23","author":"Smith","year":"2022","journal-title":"Lancet Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104698_bib60","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/S1470-2045(21)00376-4","article-title":"Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial","volume":"22","author":"de Bono","year":"2021","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104698_bib61","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.euo.2023.07.013","article-title":"Combining PARP Inhibitors and Androgen Receptor Signalling Inhibitors in Metastatic Prostate Cancer: A Quantitative Synthesis and Meta-analysis","volume":"7","author":"Messina","year":"2024","journal-title":"Eur. Urol. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104698_bib62","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.pharmthera.2013.07.003","article-title":"Androgen receptors in hormone-dependent and castration-resistant prostate cancer","volume":"140","author":"Shafi","year":"2013","journal-title":"Pharm. Ther."},{"key":"10.1016\/j.critrevonc.2025.104698_bib63","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2147\/DDDT.S15850","article-title":"Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer","volume":"6","author":"Rehman","year":"2012","journal-title":"Drug Des. Devel Ther."},{"key":"10.1016\/j.critrevonc.2025.104698_bib64","doi-asserted-by":"crossref","first-page":"1265812","DOI":"10.3389\/fonc.2023.1265812","article-title":"Double trouble for prostate cancer: synergistic action of AR blockade and PARPi in non-HRR mutated patients","volume":"13","author":"Giesen","year":"2023","journal-title":"Front Oncol."},{"issue":"21","key":"10.1016\/j.critrevonc.2025.104698_bib65","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13215417","article-title":"Androgen receptor signaling in prostate cancer and therapeutic strategies","volume":"13","author":"Jacob","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104698_bib66","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/s41419-022-05084-1","article-title":"Second generation androgen receptor antagonists and challenges in prostate cancer treatment","volume":"13","author":"Chen","year":"2022","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104698_bib67","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ccr.2012.11.010","article-title":"The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man","volume":"23","author":"Sharma","year":"2013","journal-title":"Cancer Cell"},{"issue":"480","key":"10.1016\/j.critrevonc.2025.104698_bib68","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aam7479","article-title":"Androgen receptor inhibitor-induced \"BRCAness\" and PARP inhibition are synthetically lethal for castration-resistant prostate cancer","volume":"10","author":"Li","year":"2017","journal-title":"Sci. Signal"},{"key":"10.1016\/j.critrevonc.2025.104698_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113249","article-title":"The biology behind combining poly [ADP ribose] polymerase and androgen receptor inhibition for metastatic castration-resistant prostate cancer","volume":"192","author":"Agarwal","year":"2023","journal-title":"Eur. J. Cancer"},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104698_bib70","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S1470-2045(23)00382-0","article-title":"Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial","volume":"24","author":"Saad","year":"2023","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104698_bib71","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41591-023-02704-x","article-title":"First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial","volume":"30","author":"\u2212i","year":"2024","journal-title":"Nat. Med"},{"key":"10.1016\/j.critrevonc.2025.104698_bib72","first-page":"LBA17","article-title":"ASCO 2023: TALAPRO-2: phase 3 study of talazoparib +\u2009enzalutamide versus placebo +\u2009ENZA as first-line treatment for patients with metastatic castration-resistant prostate cancer (mCRPC) harboring homologous recombination repair (HRR) gene alterations","volume":"41","author":"Neeraj Agarwal","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104698_bib73","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.23.02182","article-title":"US Food and Drug Administration approval summary: talazoparib in combination with enzalutamide for treatment of patients with homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer","author":"Heiss","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"18","key":"10.1016\/j.critrevonc.2025.104698_bib74","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1200\/JCO.22.01649","article-title":"Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer","volume":"41","author":"Chi","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104698_bib75","doi-asserted-by":"crossref","first-page":"S1495","DOI":"10.1016\/j.annonc.2022.10.194","article-title":"157O: Biomarker analysis and updated results from the phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)","volume":"33","author":"Oya","year":"2022","journal-title":"Ann. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104698_bib76","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S1470-2045(18)30365-6","article-title":"Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"19","author":"Clarke","year":"2018","journal-title":"Lancet Oncol."},{"issue":"10398","key":"10.1016\/j.critrevonc.2025.104698_bib77","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","article-title":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial","volume":"402","author":"Agarwal","year":"2023","journal-title":"Lancet"},{"issue":"27","key":"10.1016\/j.critrevonc.2025.104698_bib78","doi-asserted-by":"crossref","first-page":"23358","DOI":"10.18632\/oncotarget.4396","article-title":"Androgen receptor splice variants circumvent AR blockade by microtubule-targeting agents","volume":"6","author":"Zhang","year":"2015","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104698_bib79","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.euo.2023.01.001","article-title":"Adverse events and androgen receptor signaling inhibitors in the treatment of prostate cancer: a systematic review and multivariate network meta-analysis","volume":"6","author":"Cao","year":"2023","journal-title":"Eur. Urol. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104698_bib80","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1158\/1541-7786.MCR-18-0138","article-title":"PARP1 trapping by PARP inhibitors drives cytotoxicity in both cancer cells and healthy bone marrow","volume":"17","author":"Hopkins","year":"2019","journal-title":"Mol. Cancer Res"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104698_bib81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11523-023-01016-x","article-title":"Hematological Toxicity of PARP Inhibitors in Metastatic Prostate Cancer Patients with Mutations of BRCA or HRR Genes: A Systematic Review and Safety Meta-analysis","volume":"19","author":"Maiorano","year":"2024","journal-title":"Target Oncol."},{"issue":"98","key":"10.1016\/j.critrevonc.2025.104698_bib82","doi-asserted-by":"crossref","first-page":"37080","DOI":"10.18632\/oncotarget.26354","article-title":"A comparative pharmacokinetic study of PARP inhibitors demonstrates favorable properties for niraparib efficacy in preclinical tumor models","volume":"9","author":"Sun","year":"2018","journal-title":"Oncotarget"},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104698_bib83","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1007\/s40262-022-01167-6","article-title":"Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology","volume":"61","author":"Bruin","year":"2022","journal-title":"Clin. Pharm."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104698_bib84","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/s41416-023-02326-7","article-title":"PARP inhibitors: enhancing efficacy through rational combinations","volume":"129","author":"Bhamidipati","year":"2023","journal-title":"Br. J. Cancer"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104698_bib85","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1001\/jamaoncol.2019.1029","article-title":"Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer","volume":"5","author":"Vinayak","year":"2019","journal-title":"JAMA Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104698_bib86","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1001\/jamaoncol.2019.1048","article-title":"Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma","volume":"5","author":"Konstantinopoulos","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2025.104698_bib87","doi-asserted-by":"crossref","first-page":"S819","DOI":"10.1016\/j.annonc.2020.08.1582","article-title":"1268P JASPER: Efficacy and safety of first-line (1L) niraparib plus a programmed death receptor 1 inhibitor (PD-1i) in patients with advanced non-small cell lung cancer (NSCLC)","volume":"31","author":"Ramalingam","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104698_bib88","doi-asserted-by":"crossref","first-page":"S387","DOI":"10.1016\/j.annonc.2021.08.353","article-title":"73P Association between homologous recombination repair mutations and response to pembrolizumab (pembro) plus olaparib (ola) in metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort A biomarker analysis","volume":"32","author":"Yu","year":"2021","journal-title":"Ann. Oncol."},{"issue":"13_ement","key":"10.1016\/j.critrevonc.2025.104698_bib89","article-title":"Abstract CT178: Olaparib plus pembrolizumab in patients with previously treated advanced solid tumors with homologous recombination repair mutation (HRRm) and\/or homologous recombination deficiency (HRD): Initial results of the phase 2 KEYLYNK-007 study","volume":"81","author":"Maio","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.104698_bib90","article-title":"Pembrolizumab +\u2009Olaparib vs Pembrolizumab +\u2009Chemotherapy After Induction WithPembrolizumab +\u2009Chemotherapy for Locally Recurrent Inoperable or Metastatic TNBC: Randomized Open-Label Phase 2 KEYLYNK-009 Study","author":"Rugo","year":"2023","journal-title":"2023 SABCS"},{"issue":"22","key":"10.1016\/j.critrevonc.2025.104698_bib91","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.1200\/JCO.23.00233","article-title":"Pembrolizumab plus olaparib for patients with previously treated and biomarker-unselected metastatic castration-resistant prostate cancer: the randomized, open-label, phase III KEYLYNK-010 trial","volume":"41","author":"Antonarakis","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104698_bib92","unstructured":"Merck Provides Update on Phase 3 KEYLYNK-006 Trial Evaluating KEYTRUDA\u00ae (pembrolizumab) Plus Maintenance LYNPARZA\u00ae (olaparib) for Certain Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer, 2021. \u3008https:\/\/www.merck.com\/news\/merck-provides-update-on-phase-3-keylynk-006-trial-evaluating-keytruda-pembrolizumab-plus-maintenance-lynparza-olaparib-for-certain-patients-with-metastatic-nonsquamous-non-small-cell\/\u3009. (Accessed 26 June 2024)."},{"key":"10.1016\/j.critrevonc.2025.104698_bib93","article-title":"Results from phase 3 KEYLYNK-008: Pembrolizumab (pembro) with and without maintenance olaparib (ola) after first-line (1L) pembro plus chemotherapy (chemo) for metastatic squamous non-small-cell lung cancer (sqNSCLC)","author":"Hochmair","year":"2024","journal-title":"AACR"},{"key":"10.1016\/j.critrevonc.2025.104698_bib94","unstructured":"Avelumab and Talazoparib in Untreated Advanced Ovarian Cancer (JAVELIN OVARIAN PARP 100), 2023. \u3008https:\/\/clinicaltrials.gov\/study\/NCT03642132?tab=results\u3009. (Accessed 26 June 2024)."},{"key":"10.1016\/j.critrevonc.2025.104698_bib95","doi-asserted-by":"crossref","unstructured":"M.J.R.-P. Antonio Gonz\u00e1lez-Mart\u00edn, Florian Heitz, Ren\u00e9 Depont Christensen, Nicoletta Colombo, Toon Van Gorp, Ana Oaknin, Alexandra Leary, Lydia Gaba, Coriolan Lebreton, Luis Miguel De Sande Gonz\u00e1lez, Margarita Romeo, Andres Redondo, Maria-Pilar Barretina-Ginesta, Alejandro P\u00e9rez-Fidalgo, Ana Santaballa, Mar\u00eda Jos\u00e9 Bermejo, Ilan Bruchim, Isabelle Ray-Coquard, Fr\u00e9d\u00e9ric Selle, Primary Results From ENGOT-Ov41\/GEICO 69-O\/ANITA, A Double-Blind Placebo-Controlled Phase 3 Trial Evaluating Atezolizumab Combined With Platinum-Based Chemotherapy And Maintenance Niraparib For Recurrent Ovarian Cancer With A Platinum-Free Interval >\u20096 Months, 25th European Congress on Gynaecological Oncology, 2024.","DOI":"10.1136\/ijgc-2024-ESGO.44"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104698_bib96","first-page":"A428","volume":"33","author":"Marth","year":"2023","journal-title":"Int J. Gynecol. Cancer"},{"issue":"16_","key":"10.1016\/j.critrevonc.2025.104698_bib97","article-title":"Durvalumab +\u2009carboplatin\/paclitaxel (CP) followed by durvalumab \u00b1\u2009olaparib as first-line treatment for newly diagnosed advanced or recurrent endometrial cancer (EC) in DUO-E: Results by BRCA1\/BRCA2 mutation (BRCAm) status","volume":"42","author":"Van Nieuwenhuysen","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104698_bib98","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1158\/0008-5472.CAN-15-1965","article-title":"Inherent and Tumor-Driven Immune Tolerance in the Prostate Microenvironment Impairs Natural Killer Cell Antitumor Activity","volume":"76","author":"Pasero","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2025.104698_bib99","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2022.101543","article-title":"Ra-223 induces clustered DNA damage and inhibits cell survival in several prostate cancer cell lines","volume":"26","author":"Abramenkovs","year":"2022","journal-title":"Transl. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104698_bib100","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.7150\/thno.15311","article-title":"Potentiation of Peptide Receptor Radionuclide Therapy by the PARP Inhibitor Olaparib","volume":"6","author":"Nonnekens","year":"2016","journal-title":"Theranostics"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104698_bib101","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1158\/1535-7163.MCT-22-0583","article-title":"A Phase I Study of Combination Olaparib and Radium-223 in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) with Bone Metastases (COMRADE)","volume":"22","author":"Pan","year":"2023","journal-title":"Mol. Cancer Ther."},{"issue":"16_","key":"10.1016\/j.critrevonc.2025.104698_bib102","article-title":"LuPARP: Phase 1 trial of 177Lu-PSMA-617 and olaparib in patients with metastatic castration resistant prostate cancer (mCRPC)","volume":"41","author":"Sandhu","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"492","key":"10.1016\/j.critrevonc.2025.104698_bib103","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav4508","article-title":"Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1\/2 and RAD51","volume":"11","author":"Kaplan","year":"2019","journal-title":"Sci. Transl. Med"},{"issue":"19","key":"10.1016\/j.critrevonc.2025.104698_bib104","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1200\/JCO.21.02011","article-title":"Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial","volume":"40","author":"Liu","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104698_bib105","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1200\/JCO.21.02947","article-title":"Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984","volume":"41","author":"Kim","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104698_bib106","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1186\/s12885-024-12388-2","article-title":"The efficacy and safety of PARP inhibitors in mCRPC with HRR mutation in second-line treatment: a systematic review and bayesian network meta-analysis","volume":"24","author":"Zhu","year":"2024","journal-title":"BMC Cancer"},{"issue":"392","key":"10.1016\/j.critrevonc.2025.104698_bib107","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aal5148","article-title":"Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers","volume":"9","author":"Sun","year":"2017","journal-title":"Sci. Transl. Med"},{"issue":"13_ement","key":"10.1016\/j.critrevonc.2025.104698_bib108","article-title":"Abstract CT020: Phase I dose escalation of olaparib (PARP inhibitor) and selumetinib (MEK Inhibitor) combination in solid tumors with Ras pathway alterations","volume":"79","author":"Kurnit","year":"2019","journal-title":"Cancer Res"},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104698_bib109","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1038\/s43018-022-00438-2","article-title":"Targeting the ALK-CDK9-Tyr19 kinase cascade sensitizes ovarian and breast tumors to PARP inhibition via destabilization of the P-TEFb complex","volume":"3","author":"Chu","year":"2022","journal-title":"Nat. Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104698_bib110","doi-asserted-by":"crossref","first-page":"897","DOI":"10.3390\/ijms23020897","article-title":"Heat shock proteins in benign prostatic hyperplasia and prostate cancer","volume":"23","author":"Ratajczak","year":"2022","journal-title":"Int J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104698_bib111","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1038\/s41416-021-01664-8","article-title":"Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours","volume":"126","author":"Konstantinopoulos","year":"2022","journal-title":"Br. J. Cancer"},{"issue":"14","key":"10.1016\/j.critrevonc.2025.104698_bib112","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1200\/JCO.23.02105","article-title":"Efficacy of Poly(ADP-ribose) Polymerase Inhibitors by Individual Genes in Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer: A US Food and Drug Administration Pooled Analysis","volume":"42","author":"Fallah","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104698_bib113","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/s41467-023-35880-y","article-title":"CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer","volume":"14","author":"Tsujino","year":"2023","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104698_bib114","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1158\/0008-5472.CAN-19-3126","article-title":"ATM Loss Confers Greater Sensitivity to ATR Inhibition Than PARP Inhibition in Prostate Cancer","volume":"80","author":"Rafiei","year":"2020","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104698_bib115","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1080\/14728222.2021.1951226","article-title":"Aberrations of DNA repair pathways in prostate cancer: a cornerstone of precision oncology","volume":"25","author":"Boussios","year":"2021","journal-title":"Expert Opin. Ther. Targets"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104698_bib116","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1186\/s12885-020-06948-5","article-title":"Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: a Meta-analysis and systematic review","volume":"20","author":"Mohyuddin","year":"2020","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104698_bib117","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1200\/JCO.23.00339","article-title":"Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and\/or BRCA2 in the PROfound Trial","volume":"42","author":"Mateo","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104698_bib118","first-page":"549","article-title":"An update on the prognostic and predictive serum biomarkers in metastatic prostate cancer","volume":"10","author":"Saxby","year":"2020","journal-title":"Diagn. (Basel)"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104698_bib119","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.dnarep.2013.02.003","article-title":"Identification of miRNA modulators to PARP inhibitor response","volume":"12","author":"Neijenhuis","year":"2013","journal-title":"DNA Repair (Amst. )"},{"issue":"15","key":"10.1016\/j.critrevonc.2025.104698_bib120","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23158412","article-title":"PARP inhibitors: clinical limitations and recent attempts to overcome them","volume":"23","author":"Kim","year":"2022","journal-title":"Int J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104698_bib121","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12943-020-01227-0","article-title":"PARP inhibitor resistance: the underlying mechanisms and clinical implications","volume":"19","author":"Li","year":"2020","journal-title":"Mol. Cancer"},{"issue":"44","key":"10.1016\/j.critrevonc.2025.104698_bib122","doi-asserted-by":"crossref","first-page":"17079","DOI":"10.1073\/pnas.0806092105","article-title":"High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs","volume":"105","author":"Rottenberg","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104698_bib123","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1038\/s41467-019-09312-9","article-title":"Multiple ABCB1 transcriptional fusions in drug resistant high-grade serous ovarian and breast cancer","volume":"10","author":"Christie","year":"2019","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104698_bib124","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1038\/s41467-018-03917-2","article-title":"Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance","volume":"9","author":"Pettitt","year":"2018","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104698_bib125","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/nm.4032","article-title":"Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors","volume":"22","author":"Du","year":"2016","journal-title":"Nat. Med"},{"issue":"19","key":"10.1016\/j.critrevonc.2025.104698_bib126","doi-asserted-by":"crossref","first-page":"4318","DOI":"10.1158\/1078-0432.CCR-24-1402","article-title":"Abiraterone, Olaparib, or Abiraterone +\u2009Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway)","volume":"30","author":"Hussain","year":"2024","journal-title":"Clin. Cancer Res"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104698_bib127","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy","volume":"377","author":"James","year":"2017","journal-title":"N. Engl. J. Med"},{"issue":"32","key":"10.1016\/j.critrevonc.2025.104698_bib128","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104698_bib129","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"T. Investigators, Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N. Engl. J. Med"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104698_bib130","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":", Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N. Engl. J. Med"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104698_bib131","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N. Engl. J. Med"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104698_bib132","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N. Engl. J. Med"},{"issue":"10024","key":"10.1016\/j.critrevonc.2025.104698_bib133","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2025.104698_bib134","unstructured":"US Food and Drug Administration. XTANDI\u00ae (enzalutamide) capsules and tablets, for oral use. Astellas Pharma US, Inc. \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/203415s018,213674s005lbl.pdf\u3009."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104698_bib135","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S1470-2045(23)00148-1","article-title":"Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol","volume":"24","author":"Attard","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2025.104698_bib136","doi-asserted-by":"crossref","first-page":"S987","DOI":"10.1016\/j.annonc.2024.08.1718","article-title":"1637P Efficacy of talazoparib and enzalutamide in mCRPC patients previously treated with androgen receptor pathway inhibitors (ARPI) or docetaxel: Post hoc analysis from both cohorts in TALAPRO-2 study","volume":"35","author":"Agarwal","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104698_bib137","unstructured":"China National Medical Products Administration. PARTRUVIX\u00ae(Pamiparib) capsules, for oral use. BeiGene. \u3008https:\/\/file.wuxuwang.com\/zhuce\/ssypfiles\/15d8f47b4ccc66cc95ffc1b4ec141846%E8%AF%B4%E6%98%8E%E4%B9%A6.pdf\u3009."},{"key":"10.1016\/j.critrevonc.2025.104698_bib138","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.100887","article-title":"Cardiovascular toxicities associated with abiraterone compared to enzalutamide-A pharmacovigilance study","volume":"36","author":"Cone","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.critrevonc.2025.104698_bib139","first-page":"27","article-title":"Enzalutamide: an evidence-based review of its use in the treatment of prostate cancer","volume":"8","author":"Golshayan","year":"2013","journal-title":"Core Evid."},{"key":"10.1016\/j.critrevonc.2025.104698_bib140","unstructured":"US Food and Drug Administration. ZYTIGA\u00ae (abiraterone acetate) tablets, for oral use. Janssen Biotech, Inc. \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/202379s035lbl.pdf\u3009."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104698_bib141","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00280-021-04249-7","article-title":"Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE)","volume":"88","author":"Saad","year":"2021","journal-title":"Cancer Chemother. Pharm."},{"issue":"15_","key":"10.1016\/j.critrevonc.2025.104698_bib142","article-title":"Differential responses to taxanes and PARP inhibitors (PARPi) in ATM- versus BRCA2-mutated metastatic castrate-resistant prostate cancer (mCRPC) patients (pts)","volume":"39","author":"Su","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"4_","key":"10.1016\/j.critrevonc.2025.104698_bib143","article-title":"Neoadjuvant pamiparib plus abiraterone and ADT for high-risk\/very high-risk localized prostate cancer: Results of a prospective study","volume":"42","author":"Zhuang","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104698_bib144","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1001\/jamaoncol.2024.3074","article-title":"Olaparib Without Androgen Deprivation for High-Risk Biochemically Recurrent Prostate Cancer Following Prostatectomy: A Nonrandomized Controlled Trial","volume":"10","author":"Marshall","year":"2024","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2025.104698_bib145","doi-asserted-by":"crossref","first-page":"S980","DOI":"10.1016\/j.annonc.2024.08.1706","article-title":"1625P Fuzuloparib combined with abiraterone in the neoadjuvant treatment of localised high-risk prostate cancer (FAST-PC): A single-arm phase II study","volume":"35","author":"Zhu","year":"2024","journal-title":"Ann. Oncol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825000861?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825000861?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T14:30:14Z","timestamp":1762353014000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825000861"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":145,"alternative-id":["S1040842825000861"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104698","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Empowering PARP inhibition through rational combination: Mechanisms of PARP inhibitors and combinations with a focus on the treatment of metastatic castration-resistant prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104698","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104698"}}